Alnylam Pharmaceuticals, Inc. - ALNY Net earnings per one share for the last twelve months

Alnylam Pharmaceuticals, Inc. (ALNY) - corporate logo

Alnylam Pharmaceuticals (ALNY) possesses absolute pricing power due to the inelastic demand for the treatment of rare pathologies. This chart of net income per share YoY ttm demonstrates the inertia of the fundamental trend, where 6446.80 represents the latest metric reading. The high cost of therapy is driven by a lack of alternatives, while success is based on an innovative RNA interference platform that allows for the silencing of disease-causing genes.

ALNY: alnylam.com Net earnings per share for the last 12 months 02/11/2024 - 11/18/2026

Alnylam Pharmaceuticals - analytical breakdowns and key metrics (ALNY)

- stock quotes and analyst forecast:
Fundamental company valuation:ALNY - Alnylam Pharmaceuticals, Inc.
Brand item of Alnylam Corp

This indicator calculates the percentage change in net income per share over a rolling twelve-month period. This metric determines the scaling rate of the business's real income, separating true growth from one-off factors. For Alnylam Pharmaceuticals (ALNY), which develops its own science through licensing alliances, earnings dynamics reflect the efficiency of RNA therapy commercialization. Analyzing the 12-month YoY EPS history allows for an assessment of whether the asset's current market value is justified.

Competitor analysis

Earnings per one share for the last 12 months VRTX|INSM: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months United Therapeutics Corp. (UTHR)|BMRN (BioMarin) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)